scholarly journals Non-invasive treatment of uterine fibroids using MR guided high intensity focused ultrasound: results on quality of life, non-perfused volume ratio and size reduction over 12 months

2014 ◽  
Vol 2 (Suppl 1) ◽  
pp. A18
Author(s):  
Federica Ciolina ◽  
Fabrizio Boni ◽  
Fulvio Zaccagna ◽  
Luca Bertaccini ◽  
Beatrice Marincola ◽  
...  
Keyword(s):  
Quality Of Life ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Uterine Fibroids ◽  
Volume Ratio ◽  
High Intensity Focused Ultrasound ◽  
Size Reduction ◽  
Invasive Treatment ◽  
Non Invasive

scholarly journals A feasibility analysis of the ArcBlate MR-guided high-intensity focused ultrasound system for the ablation of uterine fibroids

2021 ◽  
Author(s):  
Chin-Jung Wang ◽  
Gigin Lin ◽  
Yi-Ting Huang ◽  
Cindy Hsuan Weng ◽  
Kai-Yun Wu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Magnetic Resonance ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Short Form ◽  
Uterine Fibroids ◽  
High Intensity Focused Ultrasound ◽  
Ablation Volume ◽  
Sf 36

Abstract Purpose Uterine fibroids are benign gynecologic tumors and commonly occur in women by the age of 50. Women with symptomatic uterine fibroids generally receive surgical intervention, while they do not favor the invasive therapies. To evaluate the feasibility and safety of a novel magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) modality, ArcBlate, in the treatment of uterine fibroids. Methods Nine patients with uterine fibroids and one patient with adenomyosis were treated with ArcBlate MRgHIFU. Tumor size and quality of life were evaluated postoperatively at 1 and 3 months by magnetic resonance imaging (MRI) and the 36-Item Short Form Survey (SF-36), respectively. Results All patients completed the ArcBlate MRgHIFU procedure and there were no treatment-related adverse effects either during the procedure or during the 3 months of follow-up. Despite limiting the ablation volume to under 50% of the treated fibroid volume as a safety precaution, tumor volumes were markedly reduced in four patients by 15.78–58.87% at 3-month post-treatment. Moreover, SF-36 scale scores had improved at 3 months from baseline by 2–8 points in six patients, indicating relief of symptoms and improved quality of life. Conclusion This study evidence demonstrates the safety and feasibility of ArcBlate MRgHIFU and suggests its potential for treating uterine fibroids.

scholarly journals Superficial malignant tumors: Non-invasive treatment with ultrasonographically guided high-intensity focused ultrasound

2009 ◽  
Vol 8 (24) ◽  
pp. 2398-2405 ◽  
Author(s):  
Chuanxing Li ◽  
Weidong Zhang ◽  
Rong Zhang ◽  
Ming Zhao ◽  
Zilin Huang ◽  
...  
Keyword(s):  
High Intensity ◽  
Focused Ultrasound ◽  
Malignant Tumors ◽  
High Intensity Focused Ultrasound ◽  
Invasive Treatment ◽  
Non Invasive

High-intensity focused ultrasound in breast pathology: non-invasive treatment of benign and malignant lesions

2014 ◽  
Vol 12 (2) ◽  
pp. 191-199 ◽  
Author(s):  
Beatrice Cavallo Marincola ◽  
Federica Pediconi ◽  
Michele Anzidei ◽  
Elena Miglio ◽  
Luisa Di Mare ◽  
...  
Keyword(s):  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Invasive Treatment ◽  
Breast Pathology ◽  
Non Invasive ◽  
Malignant Lesions
Sign in / Sign up

Export Citation Format

Share Document